$アスラン・ファーマシューティカルズ(ASLN.US)$Anticipated upcoming milestones •Late breaking poster presentation of positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of COPD at the American Thoracic Society International Conference 2024 on May 20, 2024 •Topline interim data from the farudodstat Phase 2a study in AA expected in Q3 2024•Topline data from the TREK-DX trial of eblasakimab expected at the end of 2024•Selection of a dev...
Trytosaveabit :
The advice I can give you is I’m holding it as a swing! They have until 7/23/24 to regain compliance! A lot could happen between now and then? I like it still! NFA JMO GL
$アスラン・ファーマシューティカルズ(ASLN.US)$ASLAN Pharmaceuticals Announces Late Breaking Abstract on Eblasakimab in COPD Accepted for Presentation at the American Thoracic Society International Conference
$アスラン・ファーマシューティカルズ(ASLN.US)$Rare for me but i like so I averaged down a bit! Again i can do this because i scaled in some to begin with! Im not breaking my cost positioning to do it! NFA
Trytosaveabitスレ主dSuu:
That’s the way I do 90% of my trades! In and out! Unless I’m doing a momentum/scalp trade! Then I’m all in and back out in just a few minutes!
Trytosaveabitスレ主dSuu:
Experience is the best teacher! I happy to hear that you’re doing better! Scaling in is a great way to be able to average down and not spending more than you had intended ( cost positioning ) And scaling out you’re protecting profit! While at the same time lowering your diluted cost! Which allows you to handle bigger pullbacks and stay in profit! Congrats on your learning! Stick with it and you will continue to see even more improvement
$アスラン・ファーマシューティカルズ(ASLN.US)$ASLAN PHARMACEUTICALS ANNOUNCES POSITIVE INTERIM RESULTS FROM PHASE 2 STUDY OF EBLASAKIMAB IN DUPILUMAB-EXPERIENCED ATOPIC DERMATITIS PATIENTS -Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% ach...
アスラン・ファーマシューティカルズに関するコメント
•Late breaking poster presentation of positive translational data from a head-to-head study of eblasakimab versus dupilumab in a human tissue model of COPD at the American Thoracic Society International Conference 2024 on May 20, 2024 •Topline interim data from the farudodstat Phase 2a study in AA expected in Q3 2024•Topline data from the TREK-DX trial of eblasakimab expected at the end of 2024•Selection of a dev...
Hi @Trytosaveabit May i kindly get ur opinion/ analysis on this company (No advise on buy sell).
-Interim readout of 22 patients shows unprecedented efficacy data compared to prior atopic dermatitis (AD) studies with biologics: 60.0% of dupilumab-experienced AD patients treated with 400mg eblasakimab weekly achieved EASI-90 (at least a 90% reduction in their Eczema Area Severity Index (EASI) score) and 66.7% ach...
まだコメントはありません